Boston Partners’s Novo Nordisk NVO Stock Holding History

Boston Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.33M	Sell	145,020 -5,231,804	-97%	-$248M	0.01%	480
2025 Q4	$276M	Sell	5,376,824 -194,193	-3%	-$9.93M	0.29%	122
2025 Q3	$310M	Buy	+5,571,017	New	+$326M	0.32%	108
2020 Q2	–	Sell	-2,499,362	Closed	-$75.2M	–	686
2020 Q1	$75.2M	Sell	2,499,362 -1,674,248	-40%	-$49.9M	0.15%	171
2019 Q4	$121M	Sell	4,173,610 -176,992	-4%	-$4.9M	0.16%	172
2019 Q3	$113M	Sell	4,350,602 -117,540	-3%	-$2.97M	0.15%	173
2019 Q2	$114M	Sell	4,468,142 -47,278	-1%	-$1.17M	0.15%	175
2019 Q1	$118M	Buy	4,515,420 +175,756	+4%	+$4.32M	0.16%	166
2018 Q4	$100M	Buy	+4,339,664	New	+$96.4M	0.14%	176

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Boston Partners's NVO Position: Q1 2026 in Review

Boston Partners reduced its Novo Nordisk (NVO) stake by 97% in Q1 2026, selling an estimated $248M and leaving 145,020 shares worth $5.33M. The position accounts for 0.01% of the portfolio, ranked #480.

Boston Partners first reported a position in NVO in Q4 2018 and has held it in 9 quarters since. The position peaked at $310M in Q3 2025. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Boston Partners held 145,020 shares of Novo Nordisk worth $5.33M as of Q1 2026.
Boston Partners sold 5,231,804 Novo Nordisk shares in Q1 2026, an estimated $248M.
Novo Nordisk made up 0.01% of Boston Partners's portfolio in Q1 2026, its #480 holding.
Boston Partners first reported a position in Novo Nordisk in Q4 2018 and has held it in 9 quarters since.
Boston Partners's Novo Nordisk position peaked at $310M in Q3 2025.
1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Boston Partners's 13F filing for Q1 2026, filed 11 May 2026.